EGFR and glioblastoma: Tumor-specific antibody drug conjugate Depatux-M which consists of an EGFR antibody (ABT-806) linked to monomethyl auristatin F provided positive results in recurrent EGFR-amplified GBM, but not in phase III trial due to unstable EGFR expression [20].